Current Neurology and Neuroscience Reports

, Volume 1, Issue 6, pp 501–506 | Cite as

Evidence basis for treatment of spasticity

  • David M. Dawson
Invited Commentary
  • 63 Downloads

References and Recommended Reading

  1. 1.
    Young RR: Spasticity: a review. Neurology 1994, 44 (suppl 9):12S-20S.Google Scholar
  2. 2.
    Shakespeare DT, Boggild M, Young C: Anti-spasticity agents for multiple sclerosis. Cochrane Database of Systematic Reviews 2001, 1:1–26.Google Scholar
  3. 3.
    Matthews B: Treatment of symptoms. In McAlpine’s Multiple Sclerosis, edn 3. Edited by Compton A, Ebers G, Lassman H, et al. London: Churchill Livingstone; 1998:449–455.Google Scholar
  4. 4.
    Feldman RG, Kelly Hayes M, Conomoy JP: Baclofen for spasticity in multiple sclerosis: double blind crossover and three year study. Neurology 1978, 28:1094–1098.PubMedGoogle Scholar
  5. 5.
    Basmajian J, Yucel V: Effects of GABA-derivative (BA-34647) on spasticity. Am J Phys Med 1974, 53:223–228.PubMedGoogle Scholar
  6. 6.
    Sawa GM, Paty DW: The use of baclofen in treatment of spasticity in multiple sclerosis. Can J Neurol Sci 1979, 6:351–354.PubMedGoogle Scholar
  7. 7.
    Sachais B, Logue J, Carey M: Baclofen, a new antispastic drug. Arch Neurol 1977, 34:422–428.PubMedGoogle Scholar
  8. 8.
    Brar S, Smith MB, Nelso LM, et al.: Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. Arch Phys Med Rehabil 1991, 72:186–189.PubMedGoogle Scholar
  9. 9.
    Lapierre Y, Elie R, Tetrault LP: The anti-spasticity effect of Ba 3467. A GABA derivative. Curr Ther Res 1974, 16:1059–1068.PubMedGoogle Scholar
  10. 10.
    United Kingdom Tizanidine Trial Group: A double-blind placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. The United Kingdon Tizanidine Trial Group. Neurology 1994, 44(suppl 9):S70-S78.Google Scholar
  11. 11.
    Smith C, Birnbaum G, Carter JL, et al.: Tizanidine treatment of spasticity caused by multiple sclerosis: results of a doubleblind, placebo-controlled trial. Neurology 1994, 44(suppl 9):S34-S42.PubMedGoogle Scholar
  12. 12.
    Smolenski C, Muff S, Smolneski-Kauatz S: A double-blind comparative trial of a new muscle relaxant, tizanidine (DS 103–282) and baclofen in the treatment of chronic spasticity in multiple sclerosis. Curr Med Res Opin 1981, 7:374–383.PubMedGoogle Scholar
  13. 13.
    Stien R, Nordal HJ, Oftedal SI, Slettebo M: The treatment of spasticity in multiple sclerosis: a double-blind trial of a new anti-spastic drug tizanidine compared with baclofen. Acta Neurol Scand 1987, 75:190–194.PubMedGoogle Scholar
  14. 14.
    Pelkofer M, Paulig M: Comparative double-blind study of the effectiveness and tolerance of baclofen, tetrazepam, and tizanidine in spastic movement disorders of the lower extremities. Med Klinik 1989, 84:5–8.Google Scholar
  15. 15.
    Bass B, Weinshenker B, Rice GP, et al.: Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci 1988, 15:15–19.PubMedGoogle Scholar
  16. 16.
    Mueller ME, Gruenthal M, Olson WL, Olson WH Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil 1997, 78:521–524.PubMedCrossRefGoogle Scholar
  17. 17.
    Gelenberg A, Poskanzer DC: The effect of dantrolene sodium on spasticity in multiple sclerosis. Neurology 1973, 23:1313–1315.PubMedGoogle Scholar
  18. 18.
    Luisto M, Moller K, Nuutila A, Palo J: Dantrolene sodium in chronic spasticity of varying etiology. Acta Neruol Scand 1982, 65:355–362.Google Scholar
  19. 19.
    Schmidt R, Lee R, Spehlman R: Comparison of dantrolene sodium and diazepam in the treatment of spasticity. J Neurol Neurosurg Psychiatry 1976, 39:350–356.PubMedGoogle Scholar
  20. 20.
    Barnes M: Management of spasticity—pharmacological agents. In Priniciples of Treatment of Multiple Sclerosis. Edited by Hawkins CP, Wolinsky JS. Oxford: Butterworth Heinemann; 2000:184–200.Google Scholar
  21. 21.
    From A, Heltberg A: A double-blind trial with baclofen (Lioresal) and diazepam in spasticity due to multiple sclerosis. Acta Neurol Scand 1975, 51:158–166.PubMedCrossRefGoogle Scholar
  22. 22.
    Ungerleider JT, Andrysiak T, Fairbanks L, et al.: Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Substance Abuse 1987, 7:39–50.Google Scholar
  23. 23.
    Baker D, Pryce G, Croxford JL, et al.: Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000, 404:84–87.PubMedCrossRefGoogle Scholar
  24. 24.
    Penn RD, Savoy SM, Corcos D, et al.: Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989, 320:1517–1521.PubMedCrossRefGoogle Scholar
  25. 25.
    Penn RD: Intrathecal baclofen for spasticity of spinal origin: seven years of experience. J Neurosurg 1992, 77:236–240.PubMedGoogle Scholar
  26. 26.
    Ordia JI, Fischer E, Adamski E, Spatz EL: Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity. J Neurosurg 1996, 85:453–457.Google Scholar
  27. 27.
    Ochs G, Struppler A, Meyerson BA, et al.: Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study. J Neurol Neurosurg Psychiatry 1989, 52:933–939.PubMedGoogle Scholar
  28. 28.
    van Hilten BJ, van de Beek WJ, Hoff JL, et al.: Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. N Engl J Med 2000, 343:625–630.PubMedCrossRefGoogle Scholar
  29. 29.
    Gerszten PC, Albright AL, Barry MJ: Effect on ambulation of continuous intrathecal baclofen infusion. Pediatric Neurosurg 1997, 27:40–44.CrossRefGoogle Scholar
  30. 30.
    Becker WJ, Harris CJ, Long ML, et al.: Long term intrathecal baclofen therapy in patients with intractable spasticity. Can J Neurosci 1995, 22:208–217.Google Scholar
  31. 31.
    Middel B, Kuipers-Pumeijer H, Bouma J, et al.: Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity. J Neurol Neurosurg Psychiatry 1997, 63:204–209.PubMedCrossRefGoogle Scholar
  32. 32.
    Gianino JM, York MM, Paice JA, Shott S: Quality of life: effect of reduced spasticity from intrathecal baclofen. J Neuroscience Nursing 1998, 30:47–54.Google Scholar
  33. 33.
    Creedon SD, Dijkers MP, Hinderer SR: Intrathecal baclofen for severe spasticity: a meta-analysis. Int J Rehab Health 1997, 3:171–185.Google Scholar
  34. 34.
    Hatheway CL, Dang C: Immunogenicity of neurotoxins of Clostridium botulinum. In Therapy with Botulinum Toxin. Edited by Janovic J, Hallett M. New York: Marcel Dekker; 1994:93–107.Google Scholar
  35. 35.
    Snow BJ, Tsui JK, Bhatt MH, et al.: Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 1990, 28:512–515.PubMedCrossRefGoogle Scholar
  36. 36.
    Ward A: Management of spasticity—botulinum toxin. In Principles of Treatments in Multiple Sclerosis. Edited by Hawkins CP, Wolinsky JS. Oxford: Butterworth Heinemann; 2000:201–228.Google Scholar
  37. 37.
    Brin MF: Spasticity: Etiology, Management, and the Role of Botulinium Toxin Type A. New York: Wiley; 1997.Google Scholar

Copyright information

© Current Science Inc. 2001

Authors and Affiliations

  • David M. Dawson
    • 1
  1. 1.Brigham and Women’s HospitalBostonUSA

Personalised recommendations